Sei Investments CO Supernus Pharmaceuticals, Inc. Transaction History

Sei Investments CO

$66.7 Billion
Q1 2024

A detailed history of Sei Investments CO transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Sei Investments CO holds 330,580 shares of SUPN stock, worth $8.52 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

330,580

Previous 265,828 24.36%

Holding current value

$8.52 Million

Previous $7.69 Million 46.57%

% of portfolio

0.02%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$27.11 - $35.17 $1.76 Million - $2.28 Million	64,752 Added 24.36%	330,580 $11.3 Million
Q4 2023 Feb 14, 2024	SELL	$22.72 - $29.68 $32,853 - $42,917	-1,446 Reduced 0.54%	265,828 $7.69 Million
Q3 2023 Nov 14, 2023	SELL	$27.57 - $32.91 $40,004 - $47,752	-1,451 Reduced 0.54%	267,274 $7.37 Million
Q2 2023 Aug 11, 2023	SELL	$29.91 - $38.73 $1.09 Million - $1.41 Million	-36,362 Reduced 11.92%	268,725 $8.08 Million
Q1 2023 May 12, 2023	BUY	$34.93 - $42.03 $1.31 Million - $1.58 Million	37,490 Added 14.01%	305,087 $11.1 Million

Q4 2022 Feb 10, 2023	BUY	$31.09 - $37.88 $717,432 - $874,118	23,076 Added 9.44%	267,597 $9.55 Million
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $521,876 - $641,877	18,127 Added 8.01%	244,521 $8.28 Million
Q2 2022 Aug 15, 2022	BUY	$25.33 - $34.25 $82,195 - $111,141	3,245 Added 1.45%	226,394 $6.55 Million
Q1 2022 May 13, 2022	BUY	$28.51 - $32.9 $148,137 - $170,948	5,196 Added 2.38%	223,149 $7.22 Million
Q4 2021 Feb 14, 2022	SELL	$26.37 - $34.22 $190,734 - $247,513	-7,233 Reduced 3.21%	217,953 $6.36 Million
Q3 2021 Nov 12, 2021	BUY	$23.54 - $31.39 $617,642 - $823,610	26,238 Added 13.19%	225,186 $6.01 Million
Q2 2021 Aug 06, 2021	BUY	$26.72 - $33.19 $471,474 - $585,637	17,645 Added 9.73%	198,948 $6.13 Million
Q1 2021 May 12, 2021	SELL	$24.15 - $31.45 $984,667 - $1.28 Million	-40,773 Reduced 18.36%	181,303 $4.75 Million
Q4 2020 Feb 08, 2021	SELL	$17.7 - $25.81 $332,512 - $484,866	-18,786 Reduced 7.8%	222,076 $5.59 Million
Q3 2020 Nov 06, 2020	BUY	$20.2 - $25.05 $461,186 - $571,916	22,831 Added 10.47%	240,862 $5.02 Million
Q2 2020 Aug 17, 2020	SELL	$17.09 - $24.89 $1.64 Million - $2.39 Million	-95,876 Reduced 30.54%	218,031 $5.18 Million
Q2 2020 Aug 11, 2020	BUY	$17.09 - $24.89 $2.66 Million - $3.87 Million	155,365 Added 98.0%	313,907 $7.45 Million
Q1 2020 May 14, 2020	SELL	$14.45 - $24.69 $2.25 Million - $3.84 Million	-155,435 Reduced 49.51%	158,542 $2.85 Million
Q4 2019 Feb 06, 2020	SELL	$19.93 - $29.13 $102,719 - $150,136	-5,154 Reduced 1.62%	313,977 $7.45 Million
Q3 2019 Nov 12, 2019	BUY	$25.47 - $33.37 $2.48 Million - $3.25 Million	97,345 Added 43.89%	319,131 $8.75 Million
Q2 2019 Aug 14, 2019	BUY	$29.96 - $38.87 $459,975 - $596,771	15,353 Added 7.44%	221,786 $7.38 Million
Q1 2019 May 15, 2019	SELL	$32.77 - $41.99 $311,544 - $399,198	-9,507 Reduced 4.4%	206,433 $7.27 Million
Q4 2018 Feb 13, 2019	BUY	$30.84 - $49.51 $942,994 - $1.51 Million	30,577 Added 16.5%	215,940 $10.3 Million
Q3 2018 Nov 08, 2018	SELL	$42.7 - $56.55 $1.81 Million - $2.39 Million	-42,275 Reduced 18.57%	185,363 $9.34 Million
Q2 2018 Aug 03, 2018	SELL	$44.1 - $59.85 $196,862 - $267,170	-4,464 Reduced 1.92%	227,638 $13.6 Million
Q1 2018 May 11, 2018	BUY	$37.15 - $46.9 $131,733 - $166,307	3,546 Added 1.55%	232,102 $10.6 Million
Q4 2017 Feb 08, 2018	SELL	$36.4 - $42.6 $714,786 - $836,536	-19,637 Reduced 7.91%	228,556 $9.11 Million
Q3 2017 Nov 06, 2017	BUY	$36.75 - $49.65 $9.12 Million - $12.3 Million	248,193	248,193 $9.93 Million

Others Institutions Holding SUPN

# of Institutions

260

Shares Held

57.3M

Call Options Held

84.1K

Put Options Held

61.2K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.38B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.

Account

Sei Investments CO Supernus Pharmaceuticals, Inc. Transaction History